Clinical Trial Update: A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma [Phase 2]

View source ↗

Summary

A Phase 2 study of JNJ-68284528, a BCMA-targeted CAR-T therapy, in participants with multiple myeloma is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• JNJ-68284528

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Multiple Myeloma | Phase 2 | Status: ACTIVE_NOT_RECRUITING